Data from NantHealth’s GPS Cancer platform reveals increased opportunities for HER2 directed therapy in colorectal cancer p...
January 25 2020 - 9:30AM
Business Wire
NantHealth Presented These Findings at the ASCO
2020 Gastrointestinal Cancers Symposium
NantHealth, Inc. (NASDAQ: NH), a next-generation,
evidence-based, personalized healthcare company, today announced
Results of a fifty-gene breast cancer RNA subtype classifier
applied to 167 colorectal cancer (CRC) patients during a poster
session at the 2020 Gastrointestinal Cancer Symposium sponsored by
the American Society of Clinical Oncology (ASCO).
The Symposium, held at the Moscone West Building in San
Francisco, CA from January 23-25, provides evidence-based teaching
methods and cutting-edge learning science to a diverse audience of
leaders in oncology education, doctors and care teams.
NantHealth’s presentation utilized data on whole exome (WES) DNA
tumor and paired germline and matched deep whole transcriptomic
sequencing (RNA-Seq) to identify a higher percentage of CRC
patients with HER2 signaling than conventional methods of
immunohistochemistry (IHC) or fluorescence in-situ hybridization
(FISH). ERBB2 (HER2) gene expression was evaluated using NantOmics
Nant50 gene classifier, which separates patients into subgroups
that have been well established in breast cancer. The application
of this tool to colorectal cancer proved surprising with greater
than expected HER2 positive patients with a normally expected
distribution of CMS classification (consensus molecular subtype in
CRC). This finding suggests a possible utility for this tool in a
new clinical setting. In addition, the HER2 enriched group did not
show differentially expressed mutations in other targetable genes
such as PIK3CA and BRAF, highlighting the potential importance of
HER2 targeting in this population.
“Our analysis shows that conventional testing methods may miss
potentially actionable HER2 signaling in CRC patients,” said
Sandeep “Bobby” Reddy, MD, Chief Medical Officer, NantHealth. “The
significant difference suggests that up to 40% more patients may be
eligible for HER2 directed therapies, which has implications for
drug development and clinical trials.”
Title: “Results of a fifty-gene breast cancer RNA subtype
classifier applied to 167 colorectal cancer (CRC) patients”
Authors: Sandeep K. Reddy, M.D., Tara Elisabeth Seery,
M.D., Christopher W. Szeto, Ph.D.
Poster Session and Number: Poster session C (Board
#A14)
Location: Moscone West Building
Date and Time: January 25, 2020, 6:30-7:55 AM PT and
12:15-1:45 PM PT
About NantHealth:
NantHealth, a member of the NantWorks ecosystem of companies,
provides leading solutions across the continuum of care for
physicians, payors, patients and biopharmaceutical organizations.
NantHealth enables the use of cutting-edge data and technology
toward the goals of empowering clinical decision support and
improving patient outcomes. NantHealth’s comprehensive product
portfolio combines the latest technology in payor/provider
platforms that exchange information in near-real time (NaviNet and
Eviti), connected care solutions that deliver medical device
interoperability (DCX device connectivity platform and VCX patient
vitals software) and molecular profiling services that combine
comprehensive DNA & RNA tumor-normal profiling with
pharmacogenomics analysis (GPS Cancer®). For more information,
please visit www.nanthealth.com or follow us on Twitter, Facebook
and LinkedIn.
About NantOmics:
NantOmics, a member of the NantWorks ecosystem of companies,
invented and developed the technologies that drive NantHealth’s GPS
Cancer® platform. GPS Cancer® provides actionable intelligence and
molecularly driven decision support for cancer patients and their
providers at the point of care. NantOmics is the first molecular
analysis company to pioneer an integrated approach to unearthing
molecular variances and profiles that initiate and drive cancer, by
analyzing both normal and tumor cells from the same patient and
following identified variances from DNA to RNA to protein to drug.
Having pioneered tumor-normal DNA sequencing and introduced whole
RNA transcriptomic analysis to better inform clinical treatment
decisions, NantOmics has provided molecular insights for thousands
of cancer patients.
NantOmics has a highly scalable cloud-based infrastructure
capable of storing and processing thousands of genomes a day,
computing genomic variances in near real-time and correlating
proteomic pathway analysis with quantitative gene expression and
pharmacogenomic signatures, which guides the use of
immunotherapies, chemotherapies and targeted therapies. Clinical
studies for neoepitope vaccines using NantOmics’ proprietary
technologies and novel artificial intelligence platforms are
currently underway. For more information please visit
www.nantomics.com.
Forward-Looking Statements: NantHealth
This news release contains certain statements of a
forward-looking nature relating to future events or future business
performance. Forward-looking statements can be identified by the
words “expects,” “anticipates,” “believes,” “intends,” “estimates,”
“plans,” “will,” “outlook” and similar expressions. Forward-looking
statements are based on management’s current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. Risks and uncertainties include, but are not limited to: our
ability to successfully integrate a complex learning system to
address a wide range of healthcare issues; our ability to
successfully amass the requisite data to achieve maximum network
effects; appropriately allocating financial and human resources
across a broad array of product and service offerings; raising
additional capital as necessary to fund our operations; achieving
significant commercial market acceptance for our sequencing and
molecular analysis solutions; establish relationships with, key
thought leaders or payers’ key decision makers in order to
establish GPS Cancer as a standard of care for patients with
cancer; our ability to grow the market for our Systems
Infrastructure, and applications; successfully enhancing our
Systems Infrastructure and applications to achieve market
acceptance and keep pace with technological developments; customer
concentration; competition; security breaches; bandwidth
limitations; our ability to continue our relationship with
NantOmics; our ability to obtain regulatory approvals; dependence
upon senior management; the need to comply with and meet applicable
laws and regulations; unexpected adverse events; clinical adoption
and market acceptance of GPS Cancer; and anticipated cost savings.
We undertake no obligation to update any forward-looking statement
in light of new information or future events, except as otherwise
required by law. Forward-looking statements involve inherent risks
and uncertainties, most of which are difficult to predict and are
generally beyond our control. Actual results or outcomes may differ
materially from those implied by the forward-looking statements as
a result of the impact of a number of factors, many of which are
discussed in more detail in our reports filed with the Securities
and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200125005009/en/
NANT Jen Hodson Jen@nant.com 562-397-3639
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Mar 2024 to Apr 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Apr 2023 to Apr 2024